Decoding cost-effectiveness of PNH therapies - American Society of . . . One way for clinicians to do this is to actively advocate for access to cost-effective therapies within their practices’ pharmacy formularies and make informed treatment choices that consider both patient outcomes and the financial sustainability of the health care system
Disease-modifying treatments in paroxysmal nocturnal . . . - Springer Considering the high economic burden of PNH control and management, as well as the recently approved but high costs of DMTs, this study aims to review the cost-effectiveness of FDA-approved DMTs for PNH systematically
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market North America dominates the global PNH treatment market due to the rise in the number of blood bone marrow related diseases, availability of satisfactory reimbursement policies, and increase in awareness about the early diagnosis of the disease in the region
Cost Utilization Analysis in PNH Treatment Pathways - AJMC Carlos M De Castro, MD: The cost utilization study looked at health care costs associated with PNH [paroxysmal nocturnal hemoglobinuria] It was a retrospective They used a claims database to
Paroxysmal Nocturnal Hemoglobinuria Drug Market - Pricing of complement inhibitors for PNH varies widely between developed and emerging markets, reflecting differing economic realities and healthcare infrastructures
Key Findings - ICER The discussion during the public meeting highlighted the impact of high costs associated with C5 inhibitors - the current standard of care for PNH - on accessibility and affordability, and its effect on the pricing of new PNH therapies ”
ICER Publishes Evidence Report on Treatments for Paroxysmal Nocturnal . . . ICER’s model for iptacopan, which is already FDA-approved, using a shared-savings approach (described in more detail below), suggests that the drug would need to be priced 70% lower than the current list price to meet commonly accepted thresholds
Patient Chart Audit Reveals Changing Paroxysmal Nocturnal . . . The study reveals that patient reluctance, along with cost-related barriers—particularly those tied to payer restrictions—are the primary reasons for this gap in treatment Looking ahead, the anticipated introduction of biosimilar eculizumab in 2025 has the potential to shift the PNH market
Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal . . . Using data from the 16-week randomized controlled period of the phase 3 PEGASUS trial (N = 80), we estimated the treatment cost per responder by the EBMT response category for pegcetacoplan and eculizumab in adults with PNH and a suboptimal response to eculizumab